Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Co.'s primary drug product, FYARRO, is a form of sirolimus bound to albuminnab. Co. is studying FYARRO in cancers with known mTOR pathway activation, including tumor-agnostic indications targeting specific genomic alterations that activate the mTOR pathway. In addition, Co. has ongoing studies as well as studies in planning for testing the safety and efficacy of FYARRO in combination with other targeted agents, such as Co.'s exisitng collaboration with Mirati Therapeutics, Inc. The AADI average annual return since 2018 is shown above.
The Average Annual Return on the AADI average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AADI average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AADI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|